Nicola Colclough

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

M. Raymond V. Finlay, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2014 · 602 citations · Full text

Medicine, Oncology, Pharmacology +15

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models

Stephen T. Durant, Li Zheng, Yingchun Wang et al. · Science Advances · 2018 · 312 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Matched Molecular Pairs as a Guide in the Optimization of Pharmaceutical Properties; a Study of Aqueous Solubility, Plasma Protein Binding and Oral Exposure

Andrew G. Leach, Huw Jones, David A. Cosgrove et al. · Journal of Medicinal Chemistry · 2006 · 283 citations

Pharmacy, Medicinal Chemistry, Pharmacology +16

Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)

Richard A. Ward, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2013 · 261 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs

Nicola Colclough, Kan Chen, Peter Johnström et al. · Clinical Cancer Research · 2020 · 233 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15